IU Health Arnett Clinical Research

Clinical research is crucial to the development of new treatments and new uses for current medications. Clinical research studies, or trials, test investigational drugs or devices to determine efficacy. 

Treating participants with respect and dignity, while placing their safety as top priority during a clinical trial are of the utmost importance to IU Health Arnett Clinical Research.

IU Health Arnett Clinical Research has conducted clinical trials in Lafayette, Indiana since 1990. Bamidele Adesunloye, MD, MS, FACP is the medical director of clinical research at IU Health Arnett. Dr. Adesunloye is Board Certified in Medical Oncology. At IU Health Arnett Clinical Research, we are indeed Testing Today for the Treatments of Tomorrow.

"By participating in clinical research trials, we provide an opportunity for our physicians to be on the leading edge of medical science and provide patients with earlier access to promising new medicines and technology." - Dr. Bamidele Adesunloye

Overview

Clinical research is crucial to the development of new treatments and new uses for current medications. Clinical research studies, or trials, test investigational drugs or devices to determine efficacy. 

Treating participants with respect and dignity, while placing their safety as top priority during a clinical trial are of the utmost importance to IU Health Arnett Clinical Research.

IU Health Arnett Clinical Research has conducted clinical trials in Lafayette, Indiana since 1990. Bamidele Adesunloye, MD, MS, FACP is the medical director of clinical research at IU Health Arnett. Dr. Adesunloye is Board Certified in Medical Oncology. At IU Health Arnett Clinical Research, we are indeed Testing Today for the Treatments of Tomorrow.

"By participating in clinical research trials, we provide an opportunity for our physicians to be on the leading edge of medical science and provide patients with earlier access to promising new medicines and technology." - Dr. Bamidele Adesunloye

Non-Cancer Trials

C-Diff – (Dr. Meyer’s study) – Rebiotix 2017-01: A Phase 3 Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of Rebiotix RBX2660 (microbiota suspension) for the Prevention of Recurrent Clostridium difficile Infection

Cancer Trials

We are currently participating in cancer trials for the treatment of:

Breast Cancer

Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer:  The ABC Trial

IUSCC-J13104: A randomized Phase II Study of Partial Breast Irradiation and Sequential vs. Concurrent Chemotherapy in Women with Early Stage Breast Cancer

Head & Neck

Pfizer B9991016: A randomized double-blind PH 3 study of Avelumab in combo with standard of care chemoradiotherapy (cisplatin plus definitive radiation therapy) vs. standard of care chemoradiotherapy in the front-line treatment of patients with locally advanced squamous cell carcinoma of the head and neck

Non Small Cell Lung Cancer

Dx Biosamples DxB-062 NSCLC: Collection of fresh blood from treatment naïve or progressing Stage IV M1b NSCLC cancer patients

Prostate Cancer

Johns Hopkins J1454:  Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide in Men with High-Risk PSA-Recurrent Prostate Cancer after Radical Prostatectomy (SALV-ENZA)

Dx Biosamples DxB-118:  Collection of EDTA plasma from metastatic castrate resistant prostate cancer (mCRPC) patients.

Current Trials

Non-Cancer Trials

C-Diff – (Dr. Meyer’s study) – Rebiotix 2017-01: A Phase 3 Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of Rebiotix RBX2660 (microbiota suspension) for the Prevention of Recurrent Clostridium difficile Infection

Cancer Trials

We are currently participating in cancer trials for the treatment of:

Breast Cancer

Alliance A011502: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer:  The ABC Trial

IUSCC-J13104: A randomized Phase II Study of Partial Breast Irradiation and Sequential vs. Concurrent Chemotherapy in Women with Early Stage Breast Cancer

Head & Neck

Pfizer B9991016: A randomized double-blind PH 3 study of Avelumab in combo with standard of care chemoradiotherapy (cisplatin plus definitive radiation therapy) vs. standard of care chemoradiotherapy in the front-line treatment of patients with locally advanced squamous cell carcinoma of the head and neck

Non Small Cell Lung Cancer

Dx Biosamples DxB-062 NSCLC: Collection of fresh blood from treatment naïve or progressing Stage IV M1b NSCLC cancer patients

Prostate Cancer

Johns Hopkins J1454:  Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide in Men with High-Risk PSA-Recurrent Prostate Cancer after Radical Prostatectomy (SALV-ENZA)

Dx Biosamples DxB-118:  Collection of EDTA plasma from metastatic castrate resistant prostate cancer (mCRPC) patients.

For more information about IU Health Arnett oncology/hematology clinical trials, or if you would like to participate, please contact:

Julia Keenoy, CCRP
Coordinator
Clinical Research
Phone: 765.838.6848
Fax: 765.448.7599
Email

Stephanie Middleton, LPN, CCRC
Coordinator
Clinical Research
Phone: 765.838.6871
Fax: 765.448.7599
Email

Celine Withers, RPh BCOP
Administrative Director
Indiana University Health Arnett Cancer Center
Phone: 765.838.7312
Fax: 765.448.7599
Email

Contact

For more information about IU Health Arnett oncology/hematology clinical trials, or if you would like to participate, please contact:

Julia Keenoy, CCRP
Coordinator
Clinical Research
Phone: 765.838.6848
Fax: 765.448.7599
Email

Stephanie Middleton, LPN, CCRC
Coordinator
Clinical Research
Phone: 765.838.6871
Fax: 765.448.7599
Email

Celine Withers, RPh BCOP
Administrative Director
Indiana University Health Arnett Cancer Center
Phone: 765.838.7312
Fax: 765.448.7599
Email